JUN 30, 2017 11:19 AM PDT

Genetic Test ID's Breast Cancer Patients with Lowest Risk of Death

WRITTEN BY: Xuan Pham

In cancer research, identifying the patients who do not need aggressive treatment is just as important as identifying those that do. For breast cancer, a new study reports that a 70-gene panel test can accurately diagnose a patient as “ultralow-risk” and, therefore, saving the patient from invasive, stressful, and costly treatments.

Image credit: Pixabay.com

When Angelina Jolie publicized her breast cancer prevention strategies, she invited women everywhere to examine their own breast health. And with the media’s coverage of breast cancer awareness, there has been a surge in women getting screened for breast cancer. Indeed, many patients could owe their survival from this phenomenon. Nevertheless, screening has also led many patients to be overdiagnosed. Overdiagnosis occurs when a diagnosis turns into more invasive testing and treatments that may not be necessary in the first place.

But there may soon be a molecular test that would identify women at the low end of the risk spectrum. Researchers from the University of California, San Francisco and collaborators in Sweden analyzed the potential of a 70-gene test that could diagnose a breast tumor as “indolent, or slow-growing.”

The test, called MammaPrint, was developed by Laura van ‘t Veer, a co-author on the current study. And it was already approved by the FDA about a decade ago, but its use has not been as widespread as expected.

In the new study, the research team analyzed the risk of breast cancer recurrence in the long-term, in over 1,700 breast cancer patients. In all cases, the patient’s cancer was localized and treated with radiation. In total, the team calculated the MammaPrint risk score for 652 women.

The 70-gene panel test identified that more than half of the women (58 percent) were at low risk of cancer recurrence. Of these, 95 percent survived through the 5 year mark. Furthermore, the test could predict the women with “ultralow risk” of breast cancer recurrence, those with “excellent long-term survival.”

"This is an important step forward for personalizing care for women with breast cancer," said Laura J. Esserman, a breast cancer surgeon, and the study’s lead author. "We can now test small node-negative breast cancers, and if they are in the ultralow risk category, we can tell women that they are highly unlikely to die of their cancers and do not need aggressive treatment, including radiation after lumpectomy.

For women diagnosed with ultralow risk, the 20-year breast cancer survival rate was 97 percent with tamoxifen supplement, and 94 percent without tamoxifen.

The team hopes the results of the study will convince more people that correctly diagnosing breast cancer risk is important for both ends of the risk spectrum. "This emphasizes the role that early detection can play, and how we can improve the impact of screening by focusing on those most likely to benefit," said Esserman.

"This is an exciting advance because approximately 20-25 percent of tumors diagnosed today may be ultralow risk," said Esserman. "Women who have a tumor that is classified as ultralow risk by 70-gene signature can be reassured that their long-term outcome is expected to be excellent, with or without endocrine therapy. Having a test that accurately identifies a population of women, who have very little risk to begin with, should be welcomed by patients and clinicians alike. These tools will enable doctors to better personalize therapy to safely minimize treatment and reassure women if a cancer is ultralow risk."

Additional source: University of California - San Francisco, MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 19, 2018
Cancer
JUN 19, 2018
Malignant Glioma Growth Patterns Leave Hippocampus Unaffected
Malignant glioma has specific invasive patterns of growth within the brain; one structure avoided by tumor cells is the hippocampus....
JUN 27, 2018
Immunology
JUN 27, 2018
Immune Cells Responsible for Chemo-induced Diarrhea
While studying specific immune cells in the context of chronic itching in the skin, two Washington University School of Medicine scientists discovered that...
AUG 14, 2018
Cancer
AUG 14, 2018
New Drug for Refractory Cutaneous T-cell Lymphoma
Mogamulizumab was approved by the FDA this month after a very successful Phase III clinical trial demonstrating its effectiveness in treating patients with challenging CTCL....
AUG 15, 2018
Cancer
AUG 15, 2018
Cancer Control Headway in The Last 20 Years
Learning from history and what changes have been made will continue to help drive cancer controls for the future....
SEP 02, 2018
Cell & Molecular Biology
SEP 02, 2018
Cancer Cell Lines can Evolve in the Lab
New research shows that scientists have to take steps to verify the identity of the cell lines they grow....
SEP 15, 2018
Cancer
SEP 15, 2018
Undescended testicles could lead to testicular cancer and infertility in adult males
An undescended testis (cryptorchidism) is a condition in which one of the testes or both have not descended into the right position in the scrotum at birth and either stay at the abdomen or d...
Loading Comments...